drugset / Trial / NCT00717860

A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)

NCT00717860

Phase 3 Completed 121 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.

Timeline

Start
2008-08
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Caspofungin Other / unclassified 50 mg Intravenous
Comparator Micafungin Peptide 150 mg Intravenous